Conclusion
Appropriate and timely use of Sacubitril/Valsartan has the potential to
significantly and swiftly improve LV function even in patients with
acute decompensated HF, not only in chronic HF patients.
Based on these improved outcomes, it is necessary to make a change in
clinical practice to early implement this lifesaving therapy in acute
decompensated HF patients.
Usually when medications improve quality of life, the patient’s
adherence increases. Our patient was highly adherent to his medications
after he experienced the significant improvement of his symptoms.
The outstanding impact of multimodality imaging and precisely 2D
Echocardiography is obvious in monitoring improvement of cardiac
function and deciding for revascularization
Echocardiography is the most useful test providing immediate
information, including improvement of systolic and diastolic function of
LV and RV, chamber size, and reduction in severity of valvular
regurgitation and pulmonary pressure with OMT including ARNI as in our
patient.
A cknowledgement
None.